Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Anticancer Drugs. 2014 May;25(5):482–487. doi: 10.1097/CAD.0000000000000063

Table I.

Cytotoxic and Antitumor Activity of Taxol (1)

Cytotoxic Activity
KB (human carcinoma of the nasopharynx):
ED50 =3.5 × 10−5 μg/mL
(ED50 = conc. required for 50% inhibition of growth)
Antitumor Activity
System Tested Administration Activity (% T/C)
i.p P388 Leukemia i.p. + (164)
i.p. B16 Melanoma i.p. ++ (283)
i.p. L1210 Leukemia i.p. + (139)
S.R.C* CX-1 Colon Xenograft s.c. ++ (3)
S.R.C. LX- Lung Xenograft s.c. + (8)
S.R.C. MX-1 Mammary Xenograft s.c. ++ (−77)
*

Sub-renal capsule